AIM ImmunoTech Appoints New Chief Medical Officer
Ticker: AIM · Form: 8-K · Filed: Dec 23, 2024 · CIK: 946644
Sentiment: neutral
Topics: management-change, personnel
TL;DR
AIM ImmunoTech names Dr. Michael J. Harbut as CMO, boosting oncology focus.
AI Summary
AIM ImmunoTech Inc. announced on December 19, 2024, the appointment of Dr. Michael J. Harbut as Chief Medical Officer. Dr. Harbut brings extensive experience in oncology and immunology to the role. This appointment is part of the company's ongoing efforts to advance its immuno-oncology drug candidates.
Why It Matters
The appointment of a new Chief Medical Officer with expertise in oncology and immunology could signal a renewed focus on advancing AIM ImmunoTech's drug pipeline and clinical trials.
Risk Assessment
Risk Level: medium — The appointment of a key executive like a CMO is significant, but the filing does not contain financial details or strategic shifts that would indicate a high risk.
Key Players & Entities
- AIM ImmunoTech Inc. (company) — Registrant
- Dr. Michael J. Harbut (person) — Appointed Chief Medical Officer
- December 19, 2024 (date) — Date of earliest event reported
FAQ
What is the effective date of Dr. Michael J. Harbut's appointment as Chief Medical Officer?
The filing does not explicitly state an effective date for Dr. Harbut's appointment, but the report is dated December 19, 2024, indicating the event occurred on or before this date.
What is Dr. Michael J. Harbut's background and experience?
The filing states Dr. Harbut has extensive experience in oncology and immunology, which is relevant to AIM ImmunoTech's focus.
Does this filing include any information about Dr. Harbut's compensation arrangements?
This specific filing (8-K) indicates 'Compensatory Arrangements of Certain Officers' as an item, but the details of Dr. Harbut's compensation are not provided within the text excerpt.
What is AIM ImmunoTech Inc.'s primary business?
AIM ImmunoTech Inc. is involved in the development of therapies for cancer and immune-deficiency diseases, with a focus on immuno-oncology drug candidates.
What is the significance of the 'Departure of Directors or Certain Officers' item listed in the filing?
This item suggests that there may have been or will be a departure of a director or officer, but the provided text does not specify who or when.
Filing Stats: 481 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-12-23 16:30:17
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AIM NYSE American Item
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-24-051835.txt ( ) — 206KB
- aim-20241219.xsd (EX-101.SCH) — 3KB
- aim-20241219_lab.xml (EX-101.LAB) — 33KB
- aim-20241219_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM ImmunoTech Inc. Date: December 23, 2024 By /s/ Thomas K. Equels Thomas K. Equels, CEO